Kairos Pharma (KAPA) Interest Coverage Ratio (2023 - 2024)
Kairos Pharma's (KAPA) quarterly Interest Coverage Ratio came in at 10.87 in Q4 2024, up 97.0% on a YoY basis from 5.52 in Q1 2024, and down 1424.38% quarter-over-quarter from 0.71 in Q3 2024.
Powered by 
Analysis
Kairos Pharma (KAPA) Interest Coverage Ratio (2023 - 2024) Analysis & Trends
Kairos Pharma (KAPA) has reported Interest Coverage Ratio for 2 consecutive years, with 10.87 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Interest Coverage Ratio rose 97.0% year-over-year to 10.87; the trailing twelve-month figure through Dec 2024 stood at 3.35 (changed N/A YoY), and the FY2024 full-year result was 3.5, up 91.43% from the prior year.
- Interest Coverage Ratio slipped to 10.87 in Q4 2024 per KAPA's latest filing, from 0.71 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.71 in Q3 2024 and bottomed at 363.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.58 Bn | 192.59 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 130.59 Bn | 122.74 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.61 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 60.24 Bn | 55.05 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 54.29 Bn | 49.15 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 32.96 Bn | 29.65 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.94 Bn | 30.66 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.38 Bn | 29.38 Bn | 1.16 Mn | - |
| 10 | Kairos Pharma | 30.41 Mn | 25.07 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -10.87 |
| Sep 30, 2024 | -0.71 |
| Jun 30, 2024 | -18.50 |
| Mar 31, 2024 | -17.94 |
| Dec 31, 2023 | -363.00 |
| Sep 30, 2023 | -19.13 |